CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 259 enrolled
Drug / intervention
telmisartan40/amlodipine5 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00618774
NCT00618774Phase 3Completed
CompareCT.gov

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Boehringer Ingelheim·interventional·Posted Feb 20, 2008·Updated Jun 27, 2014

In Brief

A Phase 3 clinical trial evaluating telmisartan40/amlodipine5 and telmisartan80/amlodipine5 for Hypertension. Completed, enrolled 259 participants across 7 sites.

Detailed Summary

To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 20, 2008
Enrollment StartJan 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.4 years ago

Interventions

telmisartan40/amlodipine5drug

telmisartan80/amlodipine5drug